Impact of anti–T-cell antibody infusion on outcome of RTC transplantation. (A) The 3-year probability of nonrelapse mortality after alemtuzumab-containing, ATG-containing, and T cell–replete transplant. (B) The 3-year probability of relapse after alemtuzumab-containing, ATG-containing, and T cell–replete transplants. (C) The 3-year probability of disease-free survival after alemtuzumab-containing, ATG-containing, and T cell–replete transplants after adjusting for patient age, performance score, disease, and disease status, the other significant factors. (D) The 3-year probability of overall survival after alemtuzumab-containing, ATG-containing, and T cell–replete transplants after adjusting for patient age, performance score, disease, disease status, donor type, and GVHD prophylaxis, the other significant factors.